<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225289</url>
  </required_header>
  <id_info>
    <org_study_id>88-03-27-9576</org_study_id>
    <nct_id>NCT01225289</nct_id>
  </id_info>
  <brief_title>Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients</brief_title>
  <official_title>The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to study the comparison between the effects of supplementation with
      25000 IU preformed vitamin A (retinyl palmitate) or placebo for 6 months on immune system and
      Th1/Th2 balance in patients with Multiple Sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple Sclerosis (MS) is a chronic inflammatory disease where Th1 like responses from
      myelin-specific CD4+ T cells, as secretion of pro-inflammatory IFN-g, are believed to play a
      major role in the pathogenesis. The myelin-specific T cells that mediate tissue destruction
      in MS are believed to become activated outside the central nervous system (CNS) in lymphoid
      tissue and when they cross the blood brain barrier they will re-encounter their antigen.
      Immune deviation is the redirection of the immune response from most often Th1 like responses
      to Th2 like responses, even though the opposite can also occur. Vitamin A (VA) or VA-like
      analogs known as retinoids, are potent hormonal modifiers of type 1 or type 2 responses but a
      definitive description of their mechanism(s) of action is lacking. High level dietary vitamin
      A enhances Th2 cytokine production and IgA responses, and is likely to decrease Th1 cytokine
      production. Retinoic acid inhibits IL 12 production in activated macrophages, and RA
      pretreatment of macrophages reduces IFNγ production and increases IL4 production in antigen
      primed CD4 T cells. Supplemental treatment with vitamin A or retinoic acid (RA) decreases
      IFNγ and increases IL5, IL10, and IL4 production. Thus, vitamin A deficiency biases the
      immune response in a Th1 direction, whereas high level dietary vitamin A may bias the
      response in a Th2 direction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference Serum Levels of High-sensitive C-reactive Protein (Hs-CRP), Before and After of Supplementation</measure>
    <time_frame>first day and after 6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of IL-4 Levels in Supernatant of Peripheral Blood Mononucleated Cells (PBMCs) Stimulated With Phytohemagglutinin (PHA), Before and After of Supplementation</measure>
    <time_frame>first day and after 6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of Retinol Binding Protein (RBP) / Transthyretin (TTR) Ratio, (Difference of RBP/ TTR Ratio), Before and After of Supplementation</measure>
    <time_frame>first day and after 6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Blood Mononucleated Cells (PBMCs) Proliferation Assay (BrdU Colorimetric)</measure>
    <time_frame>first day and after 6 month</time_frame>
    <description>difference of PBMCs proliferation stimulated with myelin oligodendrocyte glycoprotein (MOG), before and after of supplementation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>with Multiple Sclerosis/ vitamin A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>with Multiple Sclerosis/ placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin A</intervention_name>
    <description>25000 IU/day (one capsule per day) Vitamin A for 6 months</description>
    <arm_group_label>with Multiple Sclerosis/ vitamin A</arm_group_label>
    <other_name>Retinyl palmitate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule per day for six months</description>
    <arm_group_label>with Multiple Sclerosis/ placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who have used interferon beta in last 3 months. Patients with 1-5 EDSS

        Exclusion Criteria:

          -  Patients who have diseases which affect on Th1/Th2 balance such as asthma, active
             viral infections, and autoimmune diseases, OR

          -  Patients who have allergy to vitamin A compounds, OR

          -  Patients who have used vitamin supplements in last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Akbar Saboor Yaraghi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sima Jafarirad, PhD student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tehran University of Medical Sciences, School of Public Health Tehran, Tehran, Iran, Islamic Republic o</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tehran University of Medical Sciences, School of Public Health</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <results_first_submitted>October 29, 2013</results_first_submitted>
  <results_first_submitted_qc>February 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2014</results_first_posted>
  <last_update_submitted>February 12, 2014</last_update_submitted>
  <last_update_submitted_qc>February 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tehran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Ali Akbar Saboor Yaraghi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Vitamin A</keyword>
  <keyword>CD4-Positive T-Lymphocytes</keyword>
  <keyword>Th1 Cells</keyword>
  <keyword>Th2 Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Retinol palmitate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>With Multiple Sclerosis/ Vitamin A</title>
          <description>Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A</description>
        </group>
        <group group_id="P2">
          <title>With Multiple Sclerosis/ Placebo</title>
          <description>Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>With Multiple Sclerosis/ Vitamin A</title>
          <description>Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A</description>
        </group>
        <group group_id="B2">
          <title>With Multiple Sclerosis/ Placebo</title>
          <description>Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.22" spread="7.26"/>
                    <measurement group_id="B2" value="31.05" spread="5.94"/>
                    <measurement group_id="B3" value="32.17" spread="6.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Iran, Islamic Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference Serum Levels of High-sensitive C-reactive Protein (Hs-CRP), Before and After of Supplementation</title>
        <time_frame>first day and after 6 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Multiple Sclerosis/ Vitamin A</title>
            <description>Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A</description>
          </group>
          <group group_id="O2">
            <title>With Multiple Sclerosis/ Placebo</title>
            <description>Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Serum Levels of High-sensitive C-reactive Protein (Hs-CRP), Before and After of Supplementation</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.5"/>
                    <measurement group_id="O2" value="-0.6" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference of IL-4 Levels in Supernatant of Peripheral Blood Mononucleated Cells (PBMCs) Stimulated With Phytohemagglutinin (PHA), Before and After of Supplementation</title>
        <time_frame>first day and after 6 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Multiple Sclerosis/ Vitamin A</title>
            <description>Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A</description>
          </group>
          <group group_id="O2">
            <title>With Multiple Sclerosis/ Placebo</title>
            <description>Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day</description>
          </group>
        </group_list>
        <measure>
          <title>Difference of IL-4 Levels in Supernatant of Peripheral Blood Mononucleated Cells (PBMCs) Stimulated With Phytohemagglutinin (PHA), Before and After of Supplementation</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.2"/>
                    <measurement group_id="O2" value="1.5" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference of Retinol Binding Protein (RBP) / Transthyretin (TTR) Ratio, (Difference of RBP/ TTR Ratio), Before and After of Supplementation</title>
        <time_frame>first day and after 6 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Multiple Sclerosis/ Vitamin A</title>
            <description>Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A</description>
          </group>
          <group group_id="O2">
            <title>With Multiple Sclerosis/ Placebo</title>
            <description>Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day</description>
          </group>
        </group_list>
        <measure>
          <title>Difference of Retinol Binding Protein (RBP) / Transthyretin (TTR) Ratio, (Difference of RBP/ TTR Ratio), Before and After of Supplementation</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.2"/>
                    <measurement group_id="O2" value="-0.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral Blood Mononucleated Cells (PBMCs) Proliferation Assay (BrdU Colorimetric)</title>
        <description>difference of PBMCs proliferation stimulated with myelin oligodendrocyte glycoprotein (MOG), before and after of supplementation</description>
        <time_frame>first day and after 6 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Multiple Sclerosis/ Vitamin A</title>
            <description>Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A</description>
          </group>
          <group group_id="O2">
            <title>With Multiple Sclerosis/ Placebo</title>
            <description>Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Blood Mononucleated Cells (PBMCs) Proliferation Assay (BrdU Colorimetric)</title>
          <description>difference of PBMCs proliferation stimulated with myelin oligodendrocyte glycoprotein (MOG), before and after of supplementation</description>
          <units>absorbance units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.08"/>
                    <measurement group_id="O2" value="-0.13" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>With Multiple Sclerosis/ Vitamin A</title>
          <description>Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A</description>
        </group>
        <group group_id="E2">
          <title>With Multiple Sclerosis/ Placebo</title>
          <description>Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>MS relapsing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patien</name_or_title>
      <organization>Tehran University of Medical Sciences</organization>
      <phone>+98 912 2182815</phone>
      <email>sjafarirad@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

